Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Abzena PLC    ABZA   GB00BN65QN46

ABZENA PLC (ABZA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Abzena : Signs Protein Engineering Agreement with NYU Langone Health

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/09/2018 | 06:22pm CEST

By a News Reporter-Staff News Editor at Biotech Week -- Abzena plc (AIM: ABZA, 'Abzena'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into a master service agreement with one of America's leading academic medical centres, NYU Langone Health (New York, US). The agreement, for protein engineering and drug discovery services, will help NYU Langone's drug discovery accelerator, the Office of Therapeutics Alliances (OTA), to develop novel biopharmaceutical therapeutics (see also Abzena plc).

The first project under this master agreement centres around the development of a novel biopharmaceutical being developed by NYU OTA for the treatment of severe autoimmune disease. Abzena will provide integrated development support from its bioassay, immunology and protein engineering groups.

NYU School of Medicine is one of the USA's top-ranked medical schools. An integral part of NYU Langone Health, the School of Medicine at its core is committed to improving the human condition through medical education, scientific research, and direct patient care. Dr. Campbell Bunce, SVP, Scientific Operations, Abzena commented: "It's fantastic that our expertise and integrated offering across our biology group is being used in the development of another promising treatment. "This agreement represents another example of Abzena supporting exciting drug candidates from academic groups, utilising not just our services but also our significant biologics know-how." Dr. Nadim Shohdy, Assistant Dean and Director, Therapeutics Alliances, NYU Langone commented: "We are very excited to execute both the master agreement, and to launch this inaugural project with Abzena. "This partnership will augment NYU Langone's access to deep biologics capabilities and expertise to further enhance OTA's mission to translate the research of our faculty into therapeutic products that help patients." Notes to editors About Abzena Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and royalties on ABZENA Inside products.

Keywords for this news article include: Business, Abzena plc, Proteomics, Therapeutics, United States, Bioengineering, Medical Devices, Biopharmaceuticals, Drugs and Therapies, Health and Medicine, Protein Engineering, Biotechnology Companies, Life Sciences Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABZENA PLC
08/09ABZENA : Signs Protein Engineering Agreement with NYU Langone Health
AQ
08/09ABZENA : technology used to enhance Faron Pharma`s cancer drug
AQ
08/08ABZENA : First ABZENA Inside GMP drug substance released
PU
08/01ABZENA : Signs Protein Engineering Agreement with NYU Langone Health
AQ
07/31ABZENA : Signs Protein Engineering Agreement with NYU Langone Health
BU
07/07ABZENA : and Telix sign manufacturing and bioconjugation agreement
AQ
07/06ABZENA : Blocklisting update
PU
07/05ABZENA : signs $5.9m manufacture agreement with Telix
AQ
07/03ABZENA : and Telix sign strategic manufacturing and bioconjugation agreement
AQ
07/02ABZENA : and Telix sign manufacturing agreement
PU
More news
Financials (GBP)
Sales 2019 26,8 M
EBIT 2019 -10,2 M
Net income 2019 -9,78 M
Debt 2019 2,97 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 0,61x
EV / Sales 2020 0,63x
Capitalization 13,4 M
Chart ABZENA PLC
Duration : Period :
Abzena PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABZENA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 0,51  GBP
Spread / Average Target 715%
EPS Revisions
Managers
NameTitle
William John Edward Burt Chief Executive Officer & Director
Kenneth Thomas Cunningham Non-Executive Chairman
Brian Johnson Chief Operating Officer
Julian Matthew Smith Chief Financial Officer, Secretary & Director
James Mills Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
ABZENA PLC-79.51%17
CELLTRION, INC.--.--%28 985
IQVIA HOLDINGS INC23.80%24 472
LONZA GROUP19.94%23 836
INCYTE CORPORATION-29.84%13 790
SEATTLE GENETICS, INC.39.50%11 719